Literature DB >> 31665915

XDR-Klebsiella pneumoniae isolates harboring blaOXA-48: In vitro and in vivo evaluation using a murine thigh-infection model.

Noha A Kamel1, Wafaa N El-Tayeb1, Mona R El-Ansary2, Mohamed T Mansour3, Khaled M Aboshanab4.   

Abstract

Entities:  

Keywords:  Carbapenemases; Klebsiella pneumoniae; antibiotic combination; blaOXA-48; extensively drug-resistant; murine thigh model

Mesh：

Substances：

Year:  2019        PMID： 31665915      PMCID： PMC6963378          DOI： 10.1177/1535370219886826

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


× No keyword cloud information.
  26 in total

1.  Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice.

Authors:  Veena Venugopalan; Boris Nogid; Thy N Le; Shafiqur M Rahman; Tiffany E Bias
Journal:  Infect Dis (Lond)       Date:  2017-07-11

2.  Occurrence of OXA-48 and VIM-1 carbapenemase-producing Enterobacteriaceae in Egypt.

Authors:  Laurent Poirel; Mohammed O Abdelaziz; Sandrine Bernabeu; Patrice Nordmann
Journal:  Int J Antimicrob Agents       Date:  2012-10-04       Impact factor: 5.283

3.  Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model.

Authors:  Yun Cai; Deqing Yang; Jin Wang; Rui Wang
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

Review 4.  Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis.

Authors:  Konstantinos Z Vardakas; Andreas D Mavroudis; Maria Georgiou; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2017-12-27       Impact factor: 5.283

5.  Synergy assessed by checkerboard. A critical analysis.

Authors:  M H Hsieh; C M Yu; V L Yu; J W Chow
Journal:  Diagn Microbiol Infect Dis       Date:  1993 May-Jun       Impact factor: 2.803

Review 6.  Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients.

Authors:  Federico Perez; David Van Duin
Journal:  Cleve Clin J Med       Date:  2013-04       Impact factor: 2.321

Review 7.  Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.

Authors:  Elizabeth Temkin; Amos Adler; Anat Lerner; Yehuda Carmeli
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

8.  Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Jessica B Cprek; Jason C Gallagher
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

Review 9.  The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.

Authors:  Jian Wang; Yaping Pan; Jilu Shen; Yuanhong Xu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-04-05       Impact factor: 3.944

10.  Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.

Authors:  Bing Fan; Jie Guan; Xiumei Wang; Yulong Cong
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.